Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) (NCT06980948)
A Multicenter Phase 1 / 2 Double-blind, Randomized, Sham-controlled Dose Escalation Study to Determine Safety and Tolerability of Single Dose Intrathecal ST-503 Gene Therapy for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
🩺 Plain-English Summary (8th-Grade Level)
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Who can join: Review the eligibility criteria below.
Location: HonorHealth — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- ST-503 (GENETIC)
- Sham (No Treatment) (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- HonorHealth — Scottsdale, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- The University of California, San Diego — La Jolla, California
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH) — New York, New York
- University of North Carolina Medical Center — Chapel Hill, North Carolina
- Vanderbilt University — Nashville, Tennessee
- University of Utah — Salt Lake City, Utah
- Virginia Commonwealth University — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (510) 307-7266
Email: clinicaltrials@sangamo.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Neuropathic Pain
- Transcranial Magnetic Stimulation for Chronic Neuropathic Pain — San Francisco, California
- Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial — Toronto, Ontario
- Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN — Toronto, Ontario
Explore by condition: All Chronic Neuropathic Pain clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.